Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conference
August 29, 2018 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that it will present at Baird's 2018 Global Healthcare Conference on Wednesday, September 5 at...
FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline
August 08, 2018 14:20 ET
|
Paratek Pharmaceuticals
-- Positive vote for both the skin infections and pneumonia indications -- -- FDA decision expected in early October 2018 -- BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc....
Paratek Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Omadacycline New Drug Applications for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections
August 08, 2018 07:05 ET
|
Paratek Pharmaceuticals
BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results
August 02, 2018 16:01 ET
|
Paratek Pharmaceuticals
-- Antimicrobial Drugs Advisory Committee of FDA scheduled for August 8, 2018 to review the Company's NDAs for omadacycline -- -- Omadacycline PDUFA action date scheduled for October 2018 -- --...
Paratek Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018
July 23, 2018 07:30 ET
|
Paratek Pharmaceuticals
BOSTON, July 23, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Announces FDA Advisory Committee Date for Omadacycline
June 20, 2018 09:05 ET
|
Paratek Pharmaceuticals
BOSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus at ASM Microbe 2018
June 11, 2018 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, June 11, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018
June 07, 2018 16:05 ET
|
Paratek Pharmaceuticals
Poster presentations will include new analysis of efficacy against drug resistant S. aureus in skin infections BOSTON, June 07, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc....
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
June 01, 2018 16:30 ET
|
Paratek Pharmaceuticals
BOSTON, June 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity
May 22, 2018 16:01 ET
|
Paratek Pharmaceuticals
Data Presented During “New Insights in Acute Pulmonary Infections” Oral Session at American Thoracic Society 2018 International Conference BOSTON, May 22, 2018 (GLOBE NEWSWIRE) -- Paratek...